Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
stocks
Chart of the Week: The long term headwinds facing copper shares
stocks
Australia’s oldest REIT undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.20 | 6.50 | -0.07% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 23,050.39 | 169.37 | 0.74% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 69,591.75 | 883.21 | -1.25% |
| NZX 50 Index | 13,522.05 | 88.45 | -0.65% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,710.10 | 0.50 | -0.01% |
| SSE Composite Index | 4,083.73 | 28.72 | -0.70% |